Details of Disease

General Information of Disease (ID: DISLBW6B)

Disease Name	Schizoaffective disorder
Disease Class	6A21: Schizoaffective disorder
Definition	A disorder in which the individual suffers from both symptoms that qualify as schizophrenia and symptoms that qualify as a mood disorder (e.g., depression or bipolar disorder) for a substantial portion (but not all) of the active period of the illness; for the remainder of the active period of the illness, the individual suffers from delusions or hallucinations in the absence of prominent mood symptoms.
Disease Hierarchy	DIS4UQOT: Psychotic disorder DISLBW6B: Schizoaffective disorder
ICD Code	ICD-11 ICD-11: 6A21
Disease Identifiers	MONDO ID MONDO_0005487 MESH ID D011618 UMLS CUI C0036337 MedGen ID 11334 SNOMED CT ID 191567000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Aripiprazole	DM3NUMH	Approved	Small molecular drug	[1]
Bexarotene	DMOBIKY	Approved	Small molecular drug	[2]
Cholecalciferol	DMGU74E	Approved	Small molecular drug	[3]
Olanzapine	DMPFN6Y	Approved	Small molecular drug	[4]
Paliperidone	DM7NPJS	Approved	Small molecular drug	[5]
Quetiapine	DM1N62C	Approved	Small molecular drug	[6]
Risperidone	DMN6DXL	Approved	Small molecular drug	[7]
Ziprasidone	DMM58JY	Approved	Small molecular drug	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
N-DESMETHYLCLOZAPINE	DMVIRN3	Phase 2	Small molecular drug	[9]
Ocaperidone	DMP6B59	Phase 2	Small molecular drug	[10]
Talnetant	DMQKZDT	Phase 2	Small molecular drug	[11]
YKP-1358	DMKHVNE	Phase 1	NA	[12]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Osanetant	DMMT4PB	Discontinued in Phase 2b	Small molecular drug	[13]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SB222200	DM6X0PZ	Preclinical	Small molecular drug	[14]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 27 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
C9orf72	TTA4SHR	Limited	Genetic Variation	[15]
CALR	TTUZ7OA	Limited	Biomarker	[16]
COMT	TTKWFB8	Limited	Genetic Variation	[17]
KCNN3	TT9JH25	Limited	Genetic Variation	[18]
SST	TTWF7UG	Limited	Genetic Variation	[19]
DAO	TT7Y3EJ	Disputed	Genetic Variation	[20]
HRH1	TTTIBOJ	Disputed	Genetic Variation	[21]
HRH3	TT9JNIC	Disputed	Biomarker	[21]
MAD1L1	TTNE9U7	moderate	Genetic Variation	[22]
NPY	TT64REZ	moderate	Altered Expression	[19]
PDGFRB	TTI7421	moderate	Biomarker	[23]
TCF7L2	TT80QAL	moderate	Biomarker	[24]
AVP	TTJ8EWH	Strong	Biomarker	[25]
BDNF	TTSMLOH	Strong	Genetic Variation	[26]
DRD3	TT4C8EA	Strong	Genetic Variation	[27]
DRD5	TTS2PH3	Strong	Biomarker	[28]
GABRR1	TT6XFEU	Strong	Genetic Variation	[29]
GRIA1	TTVPQTF	Strong	Biomarker	[30]
GRIN1	TTLD29N	Strong	Biomarker	[28]
HTR1B	TTK8CXU	Strong	Biomarker	[28]
HTR2A	TTJQOD7	Strong	Genetic Variation	[31]
NR3C1	TTOZRK6	Strong	Biomarker	[28]
NTRK1	TTTDVOJ	Strong	Biomarker	[28]
PLA2G4A	TTT1JVS	Strong	Genetic Variation	[32]
PRKCA	TTFJ8Q1	Strong	Biomarker	[33]
RGS6	TTJ96M8	Strong	Genetic Variation	[34]
SNAP25	TTYQWA0	Strong	Biomarker	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 27 DTT(s)

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
PRODH	DEVJIHS	Strong	Genetic Variation	[35]
SAT1	DEMWO83	Strong	Biomarker	[36]
------------------------------------------------------------------------------------

This Disease Is Related to 40 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PCDH11X	OTLICG18	Limited	Genetic Variation	[37]
CAPN10	OTS9LJW4	Disputed	Genetic Variation	[24]
DLX4	OTLWVCN4	Disputed	Biomarker	[38]
DNTT	OTFSEF12	Disputed	Genetic Variation	[23]
MCCC2	OTQDHSMI	Disputed	Biomarker	[39]
NEUROD2	OTJMMX9K	Disputed	Biomarker	[40]
ACTL7A	OT840164	moderate	Genetic Variation	[41]
ARHGEF10L	OTUAMHIZ	moderate	Genetic Variation	[41]
ATP6V1E2	OTNNHL6G	moderate	Genetic Variation	[41]
C11orf21	OTJGXDHK	moderate	Genetic Variation	[41]
CABLES1	OTMN4XSX	moderate	Genetic Variation	[41]
CCDC102B	OTVDZVD0	moderate	Genetic Variation	[41]
CSMD1	OTIVDSC4	moderate	Genetic Variation	[22]
IPO8	OTBHGNKT	moderate	Genetic Variation	[41]
ITIH1	OTSXJGQF	moderate	Genetic Variation	[22]
KSR2	OTSMUL59	moderate	Genetic Variation	[41]
LMO7	OTDLY6TC	moderate	Genetic Variation	[41]
LTN1	OTIW2HTX	moderate	Genetic Variation	[41]
MED15	OT0D0JVD	moderate	Biomarker	[42]
NEUROG1	OTMJZP9G	moderate	Biomarker	[43]
PCDH12	OT2VANLI	moderate	Genetic Variation	[41]
PLCB4	OTPA0QHW	moderate	Genetic Variation	[41]
RPN2	OTJ1SKOA	moderate	Genetic Variation	[41]
SDCCAG8	OTV2ZGV9	moderate	Genetic Variation	[22]
STX2	OTO2IDDR	moderate	Genetic Variation	[41]
TMPRSS5	OTERB7Z4	moderate	Genetic Variation	[41]
ARID3B	OTUP9MS4	Strong	Biomarker	[44]
CPLX1	OT7UIGTP	Strong	Biomarker	[28]
CPLX2	OTU5QWFH	Strong	Biomarker	[28]
DTNBP1	OT9UQT2S	Strong	Genetic Variation	[45]
EGR3	OTGPJIRA	Strong	Biomarker	[46]
GRID1	OTJ3WIKC	Strong	Biomarker	[47]
PPM1K	OTNZ4N4E	Strong	Biomarker	[44]
PVALB	OTZW1WVQ	Strong	Biomarker	[28]
RBM12	OTQYZ3LQ	Strong	Biomarker	[48]
RTN3	OTGZ51QF	Strong	Genetic Variation	[33]
SAFB	OTGRV2LW	Strong	Genetic Variation	[33]
SELENBP1	OT3NZNTR	Strong	Biomarker	[49]
SULT4A1	OT7AL3KJ	Strong	Biomarker	[50]
NPAS2	OTMRT2TS	Definitive	Biomarker	[46]
------------------------------------------------------------------------------------


⏷ Show the Full List of 40 DOT(s)

References

1	Aripiprazole FDA Label
2	Bexarotene FDA Label
3	Cholecalciferol FDA Label
4	Olanzapine FDA Label
5	Paliperidone FDA Label
6	Quetiapine FDA Label
7	Risperidone FDA Label
8	Ziprasidone FDA Label
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 333).
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 46).
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2132).
12	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2110).
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2131).
15	C9orf72 repeat expansions that cause frontotemporal dementia are detectable among patients with psychosis.Psychiatry Res. 2016 Jan 30;235:200-2. doi: 10.1016/j.psychres.2015.12.007. Epub 2015 Dec 8.
16	Novel mutations in the calreticulin gene core promoter and coding sequence in schizoaffective disorder.Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):706-709. doi: 10.1002/ajmg.b.31036.
17	Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis.Int J Neuropsychopharmacol. 2016 Apr 29;19(5):pyv132. doi: 10.1093/ijnp/pyv132. Print 2016 May.
18	Association study of CAG repeats in the KCNN3 gene in Israeli patients with major psychosis.Psychiatr Genet. 2003 Sep;13(3):143-50. doi: 10.1097/00041444-200309000-00002.
19	NPY mRNA expression in the prefrontal cortex: Selective reduction in the superficial white matter of subjects with schizoaffective disorder.Schizophr Res. 2009 Dec;115(2-3):261-9. doi: 10.1016/j.schres.2009.09.014. Epub 2009 Oct 4.
20	Evidence for association and epistasis at the DAOA/G30 and D-amino acid oxidase loci in an Irish schizophrenia sample.Am J Med Genet B Neuropsychiatr Genet. 2007 Oct 5;144B(7):949-53. doi: 10.1002/ajmg.b.30452.
21	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.World J Biol Psychiatry. 2018;19(sup3):S97-S105. doi: 10.1080/15622975.2016.1262061. Epub 2016 Dec 15.
22	GWAS meta analysis identifies TSNARE1 as a novel Schizophrenia / Bipolar susceptibility locus.Sci Rep. 2013 Oct 29;3:3075. doi: 10.1038/srep03075.
23	Weak association of the platelet-derived growth factor beta (PDGFB) and PDGF receptor beta (PDGFRB) genes with schizophrenia and schizoaffective disorder.World J Biol Psychiatry. 2011 Mar;12(2):127-33. doi: 10.3109/15622975.2010.520333. Epub 2010 Oct 18.
24	Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder.Schizophr Res. 2009 Oct;114(1-3):50-6. doi: 10.1016/j.schres.2009.07.008. Epub 2009 Jul 29.
25	Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biol Psychiatry. 1987 Apr;22(4):453-62. doi: 10.1016/0006-3223(87)90167-3.
26	BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis.Pharmacogenomics J. 2019 Jun;19(3):269-276. doi: 10.1038/s41397-018-0041-5. Epub 2018 Sep 5.
27	Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Hum Psychopharmacol. 2008 Jun;23(4):267-74. doi: 10.1002/hup.930.
28	Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium.Mol Psychiatry. 2004 Jun;9(6):609-20, 544. doi: 10.1038/sj.mp.4001471.
29	Variation at the GABAA receptor gene, Rho 1 (GABRR1) associated with susceptibility to bipolar schizoaffective disorder.Am J Med Genet B Neuropsychiatr Genet. 2010 Oct 5;153B(7):1347-9. doi: 10.1002/ajmg.b.31108.
30	Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?.Neuropharmacology. 2012 Mar;62(3):1263-72. doi: 10.1016/j.neuropharm.2011.06.005. Epub 2011 Jun 15.
31	Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients.Hum Psychopharmacol. 2010 Jun-Jul;25(4):347-52. doi: 10.1002/hup.1114.
32	BanI polymorphism of cytosolic phospholipase A2 gene is associated with age at onset in male patients with schizophrenia and schizoaffective disorder.Prostaglandins Leukot Essent Fatty Acids. 2008 Jun;78(6):351-60. doi: 10.1016/j.plefa.2008.04.006. Epub 2008 Jun 17.
33	Evidence for rare and common genetic risk variants for schizophrenia at protein kinase C, alpha.Mol Psychiatry. 2010 Nov;15(11):1101-11. doi: 10.1038/mp.2009.96. Epub 2009 Sep 29.
34	Genome-wide association analysis to predict optimal antipsychotic dosage in schizophrenia: a pilot study.J Neural Transm (Vienna). 2016 Mar;123(3):329-38. doi: 10.1007/s00702-015-1472-7. Epub 2016 Jan 28.
35	Hyperprolinemia is not associated with childhood onset schizophrenia.Am J Med Genet B Neuropsychiatr Genet. 2006 Mar 5;141B(2):192. doi: 10.1002/ajmg.b.30263.
36	Discovery and validation of blood biomarkers for suicidality.Mol Psychiatry. 2013 Dec;18(12):1249-64. doi: 10.1038/mp.2013.95. Epub 2013 Aug 20.
37	ProtocadherinX/Y, a candidate gene-pair for schizophrenia and schizoaffective disorder: a DHPLC investigation of genomic sequence.Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):1-9. doi: 10.1002/ajmg.b.30036.
38	Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder.Am J Hum Genet. 2003 Jul;73(1):49-62. doi: 10.1086/376547. Epub 2003 Jun 11.
39	What does the Managing Emotions branch of the MSCEIT add to the MATRICS consensus cognitive battery?.Schizophr Res. 2018 Jul;197:414-420. doi: 10.1016/j.schres.2018.02.018. Epub 2018 Feb 24.
40	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment.Cogn Neuropsychiatry. 2017 Jul;22(4):280-297. doi: 10.1080/13546805.2017.1322502. Epub 2017 May 4.
41	Genome-wide association studies of smooth pursuit and antisaccade eye movements in psychotic disorders: findings from the B-SNIP study.Transl Psychiatry. 2017 Oct 24;7(10):e1249. doi: 10.1038/tp.2017.210.
42	Association study between CAG trinucleotide repeats in the PCQAP gene (PC2 glutamine/Q-rich-associated protein) and schizophrenia.Am J Med Genet B Neuropsychiatr Genet. 2003 Jan 1;116B(1):32-5. doi: 10.1002/ajmg.b.10008.
43	Basic helix-loop-helix transcription factor NEUROG1 and schizophrenia: effects on illness susceptibility, MRI brain morphometry and cognitive abilities.Schizophr Res. 2008 Dec;106(2-3):192-9. doi: 10.1016/j.schres.2008.08.009. Epub 2008 Sep 16.
44	A Bayesian model comparison approach to test the specificity of visual integration impairment in schizophrenia or psychosis.Psychiatry Res. 2018 Jul;265:271-278. doi: 10.1016/j.psychres.2018.04.061. Epub 2018 May 7.
45	Clinical and molecular genetics of psychotic depression.Schizophr Bull. 2013 Jul;39(4):766-75. doi: 10.1093/schbul/sbt040. Epub 2013 Mar 19.
46	Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophrenia.Bipolar Disord. 2009 Nov;11(7):701-10. doi: 10.1111/j.1399-5618.2009.00756.x.
47	Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios.Am J Hum Genet. 2005 Dec;77(6):918-36. doi: 10.1086/497703. Epub 2005 Oct 28.
48	Truncating mutations in RBM12 are associated with psychosis.Nat Genet. 2017 Aug;49(8):1251-1254. doi: 10.1038/ng.3894. Epub 2017 Jun 19.
49	The utility of SELENBP1 gene expression as a biomarker for major psychotic disorders: replication in schizophrenia and extension to bipolar disorder with psychosis.Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):686-9. doi: 10.1002/ajmg.b.30664.
50	SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.Pharmacogenomics. 2014;15(12):1557-64. doi: 10.2217/pgs.14.105.